Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A real-world experience of effectiveness and safety study of ZX008 for the treatment of refractory Dravet syndrome: Expanded access program in US

Next Previous
Search
Trial Profile

A real-world experience of effectiveness and safety study of ZX008 for the treatment of refractory Dravet syndrome: Expanded access program in US

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 21 Jan 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fenfluramine (Primary) ; Cannabidiol; Clobazam; Stiripentol; Valproate
  • Indications Dravet syndrome; Seizures
  • Focus Adverse reactions; Expanded access; Therapeutic Use

    • Most Recent Events

    • 08 Dec 2020 Results assessing this real-world Early Access Program experience clinical benefit and tolerability of fenfluramine in adults with DS in comparison to children and adolescents , presented at the 74th Annual Meeting of the American Epilepsy Society.
    • 20 May 2020 New trial record
    • 01 May 2020 Results presented at the 72nd Annual Meeting of the American Academy of Neurology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top